GKOS
GLAUKOS Corp
$152.72
-2.35 (-1.52%)
At close · Jul 10
Market Cap
$8.97B
Shares
58,733,911
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$152.72
Open$154.05
Day$143.11–156.60
52W$73.16–156.60
Avg vol 30d998K
Short int4.4M · 7.6% float · 4.5d
Short vol54%
Last earningsMay 26, 2026
DataJan 2020–Jul 2026
Filing10-Q · Apr 30
Up next
Next earnings call
Aug 29, 2026
Est · unconfirmed
· in 7 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+37%
above
Price vs 50-day avg
+15%
above
RSI (14)
68
neutral
MACD trend
Positive
52-week position
95%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+25%
trailing
6-month return
+33%
trailing
YTD return
+35%
this year
Relative strength
+24%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $132 › 200d $112 — 50d above 200d
Institutional flow
Accumulating
18 of 338 funds reported for Jun 30 · net +87.5K sh shares · +4 new
Insider flow
Distributing
Net -$5.8M over 90 days · 100% sells
Short interest
Rising
7.58% of float · ▲ +6.6% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
338 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+32%
Y/Y
Gross margin
56%
contracting
EPS growth
−18%
Y/Y
Free cash flow
$-22.5M
Balance sheet
$81.1M
net cash
Quant / Vol
risk profile
Volatility
54%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Apr 29, 2026
Net sales
· 2026
Maintained
$620M – $635M
prior FY $507.44M
midpoint +23.7% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+37%
Bullish
Price vs 50-day avg
+15%
Bullish
RSI (14)
68
Neutral
MACD trend
Positive
Bullish
52-week position
95%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $132 › 200d $112 — 50d above 200d
Institutional flow
Accumulating
18 of 338 funds reported for Jun 30 · net +87.5K sh shares · +4 new
Insider flow
Distributing
Net -$5.8M over 90 days · 100% sells
Short interest
Rising
7.58% of float · ▲ +6.6% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
338 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $73
Now $153 · 95%
52-wk high $157
vs 200-day avg +37%
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP gross margin non-GAAP | 84% | Q1 2026 | — |
| Non-GAAP loss from operations non-GAAP | -$10.5M | Q1 2026 | — |
| Non-GAAP SG&A expenses non-GAAP | $92.2M | Q1 2026 | — |
| covered commercial lives with Epioxa access pathways | 100M | Q1 2026 call | — |
| U.S. population reach via O2N systems | 65% | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GKOS
this stock
GLAUKOS Corp
|
$8.97B | +35.3% | +32.3% | — | 7.6% |
|
ABT
Abbott Laboratories
|
$163.61B | -24.7% | +5.7% | 26.3 | 1.3% |
|
SYK
Stryker Corp
|
$126.42B | -5.9% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$107.36B | -12.0% | +8.4% | 22.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.54B | -53.0% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GKOS | +3.0% | +24.7% | +33.4% | +9.3% | +35.3% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +1.6% | +20.6% | +24.3% | +8.2% | +24.6% |
Key facts
CIK
1192448
CUSIP
377322102
13F (30d)
16 filings
16 filers
Visit website
Investor relations